Pulmonx Corp stock (US74586W1018): Q1 2026 results highlight growth path in minimally invasive lung treatments
Pulmonx Corp reported its Q1 2026 results, detailing the progress and demand for its Zephyr endobronchial valve therapy for severe COPD and emphysema. The company's revenue is driven by the sales of these valves and associated tools, emphasizing physician adoption, reimbursement frameworks, and expanding treatment centers. Despite being a smaller-cap medical device company, Pulmonx focuses on minimally invasive treatments and its market capitalization is around $56.59 million, reflecting its niche but growing position in interventional pulmonology.
Pulmonx Corp stock (US74586W1018): credit line and margin focus keep lung care specialist in the spotlight
Pulmonx Corp, a minimally invasive lung treatment specialist, is navigating a growth pause by focusing on margin improvement and strengthened liquidity. The company secured a new $60 million interest-only credit facility and ended the quarter with $61.6 million in cash equivalents. This financial flexibility, alongside disciplined cost control and continued investment in physician education, is crucial as Pulmonx works to reaccelerate growth for its Zephyr valve system, which treats severe emphysema.
Pulmonx (NASDAQ: LUNG) secures $40M Perceptive loan and ends Q1 with $61.6M cash
Pulmonx (NASDAQ: LUNG) reported Q1 2026 results including $20.6 million in revenue, a net loss of $13.7 million, and an improved gross margin of 77.9%. The company secured a new $40 million senior secured term loan from Perceptive Credit Holdings V, LP, replacing a prior facility, and ended the quarter with $61.6 million in cash and equivalents. Pulmonx continues to invest in research and development and sales and marketing, expecting ongoing operating losses.
Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary
Pulmonx Corp reported its first-quarter 2026 results, showing a decline in revenue to $20.59 million from $22.54 million year-over-year. The company posted a net loss of ($13.65 million) or ($0.33) per diluted share. Key factors included lower unit sales and lost China shipments, though the company continues to see positive commercial momentum with reimbursement gains and is investing in product development.
Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts
Pulmonx Corporation (NASDAQ:LUNG) has received a consensus "Hold" rating from analysts, with an average one-year price target of $5.38, significantly above its current trading price of around $1.35. The company remains unprofitable, reporting a Q1 EPS of $(0.33) and negative net margin and ROE, with analysts forecasting a full-year EPS of -$1.12. Despite insider selling, institutional ownership is high, with some major firms recently increasing their stakes.
Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen
Pulmonx (NASDAQ:LUNG) was downgraded to a "sell" rating by Wall Street Zen. Despite this, the consensus rating from other analysts remains "Hold" with an average target price of $5.38. The company is currently unprofitable, and its CEO recently sold a significant number of shares, although institutional ownership is high.
Pulmonx Corporation (NASDAQ:LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation reported Q1 2026 revenue of $20.6 million, a 9% decrease from the prior year, but reiterated its full-year 2026 revenue guidance of $90 million to $92 million. The company is focused on reaccelerating U.S. sales growth, advancing its AeriSeal program, and aligning cost structure, expecting a return to double-digit growth in the second half of 2026. Despite a temporary halt in sales to China due to pending registration renewal, other international markets showed solid growth.
Pulmonx Corp expected to post a loss of 33 cents a share - Earnings Preview
Pulmonx Corp (LUNG) is projected to report a loss of 33 cents per share, according to this earnings preview. The information was sourced from Refinitiv and suggests an upcoming financial announcement for the company.
Is Pulmonx (LUNG) 85.3% Undervalued After Q1 2026 Beats? EPS -$0
Pulmonx Corp (LUNG) reported its Q1 2026 results, surpassing revenue and EPS estimates with $20.6 million in revenue and a GAAP EPS of -$0.33. Despite a 9% year-over-year revenue decline, the company saw gross margin expand to 78% and attributed international declines to a temporary registration pause in China. GuruFocus considers LUNG 85.3% undervalued, trading at a significant discount to its intrinsic value.
Pulmonx (LUNG) Projects 2026 Revenue Between $90M and $92M
Pulmonx Corp (LUNG) has reaffirmed its 2026 revenue guidance, projecting between $90 million and $92 million, with a robust gross margin near 75%. Despite anticipated operating expenses between $113 million and $115 million, the company, which specializes in minimally invasive treatments for severe emphysema, shows strength in growth but has concerns regarding profitability and financial stability. Its GF Score™ of 59 and a low price-to-sales ratio of 0.55 suggest potential undervaluation, though caution is advised due to insider selling and financial health indicators.
Earnings call transcript: Pulmonx Q1 2026 reveals mixed results, stock dips
Pulmonx (LUNG) reported mixed financial results for Q1 2026, with an EPS of -$0.33, beating estimates, but revenue of $20.6 million, missing forecasts. The stock dropped 0.81% in aftermarket trading, nearing its 52-week low, due to investor concerns over the revenue miss and continued net losses. Despite the challenges, the company is focused on re-accelerating U.S. sales, advancing its AeriSeal program to expand its market, and aligning its cost structure for profitability, with management expressing confidence in returning to double-digit growth by year-end.
Pulmonx (NASDAQ: LUNG) Q1 revenue falls 9% but 2026 outlook reaffirmed
Pulmonx Corporation reported a 9% decrease in Q1 2026 revenue to $20.6 million, largely due to a lack of sales into China. Despite the revenue fall, the company improved gross margins to 78% and narrowed its net loss, reaffirming its full-year 2026 revenue guidance of $90–$92 million. Management highlighted refreshed U.S. commercial strategies and a fully staffed global sales organization to drive future growth.
Pulmonx Reports First Quarter 2026 Financial Results
Pulmonx Corporation reported its financial results for the first quarter of 2026, with worldwide revenue reaching $20.6 million, a 9% decrease year-over-year. The company affirmed its full-year 2026 revenue guidance of $90 million to $92 million and expects to achieve sequential improvements in revenue growth.
No China sales cut Pulmonx revenue 9%, but 2026 forecast holds
Pulmonx (Nasdaq: LUNG) reported a 9% year-over-year revenue decrease in Q1 2026 to $20.6 million, primarily due to the absence of sales in China, though ex-China international revenue rose by 22%. Despite the revenue decline, the company saw improved gross margin at 78% and a reduced net loss, and reaffirmed its full-year 2026 revenue guidance of $90 million to $92 million. Pulmonx also refinanced its debt with a new 5-year interest-only credit facility extending maturity to 2031, providing financial flexibility.
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
Pulmonx Corporation, a leader in minimally invasive treatments for severe lung disease, has announced it will present at the Bank of America Securities 2026 Health Care Conference on May 12, 2026, in Las Vegas. A webcast of the presentation will be available on the Investors section of the company's website. Pulmonx focuses on devices like the Zephyr® Endobronchial Valve for patients with severe emphysema/COPD.
Pulmonx webcast set for May 12 Bank of America health conference
Pulmonx (Nasdaq: LUNG) will present at the Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET. A live and archived webcast of the presentation will be available in the Investors section of the company's website. The announcement highlights Pulmonx's ongoing investor relations efforts, following recent positive news regarding earnings and a new credit facility, with the stock currently trading below its 52-week high.
Pulmonx (LUNG) Projected to Post Earnings on Wednesday
Pulmonx (NASDAQ:LUNG) is projected to release its Q1 2026 earnings after market close on Wednesday, April 29th, with analysts forecasting an EPS of ($0.33) and revenue of $20.431 million. The company reported better-than-expected EPS in the previous quarter and currently holds a "Hold" consensus rating from analysts with an average target price of $5.38. Insider selling, primarily by CEO Glendon E. French III, and high institutional ownership are also noted.
Executive pay and board votes at Pulmonx (NASDAQ: LUNG) 2026 meeting
Pulmonx (NASDAQ: LUNG) will hold its virtual 2026 Annual Meeting on June 4, 2026, where shareholders will vote on electing three Class III directors, ratifying BDO USA, LLP as the independent auditor, and a non-binding advisory "say-on-pay" proposal for executive compensation. The company's executive compensation program emphasizes a mix of base salary, performance-based cash bonuses, and equity awards, including performance stock units, designed to align executive interests with long-term shareholder value. The 2025 bonus plan paid out 20.6% of target due to revenue falling below the threshold, while Adjusted EBITDA and limited strategic goals were partly achieved, and recent executive transitions for CEO Glendon French and COO/CFO Derrick Sung included performance-based equity grants.
[ARS] Pulmonx Corp SEC Filing
This article announces an ARS SEC filing by Pulmonx Corp (LUNG) accepted on April 22, 2026. The filing has a low impact and neutral sentiment, and the full document is available in PDF format via SEC EDGAR. The article also provides a brief overview of Pulmonx Corp's stock and recent news and SEC filings.
How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk
Pulmonx's investment narrative is re-centering around a lower US$5 price target, despite its fair value estimate remaining at US$5.17 per share. Bullish analysts view this as a more attainable goal, while bearish commentators see it as a sign of reduced near-term expectations and persistent execution risks. The company issued 2026 revenue guidance between US$90-US$92 million, with its intrinsic value model remaining largely unchanged.
Pulmonx sets April 29 earnings release, 4:30 p.m. ET webcast
Pulmonx (Nasdaq: LUNG) announced it will release its first quarter 2026 financial results on Wednesday, April 29, 2026, after market close. Following the release, the company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with a live and archived webcast available on its Investors website. The announcement follows a pattern from previous earnings reports that have positively impacted stock movement.
Pulmonx Corp stock (US74586W1018): Is its airway treatment edge strong enough to unlock new upside?
Pulmonx Corp, a medtech company, specializes in providing innovative, minimally invasive lung devices, specifically Zephyr Valves, for treating severe emphysema. The article highlights Pulmonx's strong position in the U.S. market, supported by clinical evidence, FDA approval, and Medicare reimbursement, catering to a significant unmet need in COPD treatment. While acknowledging potential risks such as physician training challenges and reimbursement changes, the article suggests that the company's focus on a niche market and robust clinical data could drive sustained growth for investors.
Pulmonx Corp stock (US74586W1018): Is its airway treatment edge strong enough to unlock new upside?
Pulmonx Corp (LUNG) specializes in minimally invasive devices, like the Zephyr Endoluminal Valve System, for treating severe emphysema. The company targets the growing COPD market, particularly in the U.S. with established Medicare reimbursement, leveraging strong clinical evidence and a focus on expanding treatment centers. While analysts are optimistic about its growth potential, investors should monitor procedure adoption rates, international expansion, and the company's cash burn.
Pulmonx Insiders Forfeit On 14% Gains After Selling Stock
Insiders at Pulmonx Corporation sold US$371k worth of stock in the past year, which was a beneficial move as the stock price has since fallen below their average selling price of US$1.84. Recent significant insider selling of US$141k in the last three months, with no purchases, raises caution among investors. While insiders own 5.2% of the company, this figure is not considered impressive, leading to a cautious outlook on the stock.
Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG)
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership of Pulmonx Corp Common Stock (LUNG). This change, effective January 12, 2026, is due to an internal realignment under SEC Release No. 34-39538, which now requires certain Vanguard subsidiaries to report their holdings separately. The filing confirms Vanguard itself no longer holds beneficial ownership in Pulmonx.
If You Invested $1,000 in Pulmonx Corp (LUNG)
This article analyzes the historical performance of a $1,000 investment in Pulmonx Corp (LUNG), a medical technology company focused on COPD treatments. Over the past 10 years, an investment in LUNG would have significantly underperformed the S&P 500, resulting in a substantial loss. The article also provides detailed information about Pulmonx Corp's products, business model, and financial reporting.
LUNG SEC Filings - Pulmonx Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Pulmonx Corporation (LUNG) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights key events such as financial results, executive changes, and equity compensation structures while offering AI-powered summaries to help investors understand the documents quickly. Recent Form 4 filings detail insider share dispositions for tax withholding related to vested restricted stock units.
Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther
Pulmonx Corp (NASDAQ: LUNG) stock has significantly declined year-to-date, trading near multi-year lows despite strong revenue beats and expanding adoption of its Zephyr Valve system for emphysema treatment. Analysts project substantial upside potential, with price targets implying a 367% increase, driven by the company's growth in the respiratory medtech market, particularly in Europe. The company is prioritizing R&D and sales expansion, with a clean balance sheet and sufficient liquidity, aiming for profitability inflection in the coming years.
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33)
Pulmonx (LUNG) reported its 2025 financial results, with revenue reaching $90.5 million, an 8.0% increase year-over-year due to higher procedure volumes. The company significantly narrowed its loss per share to $(1.33) from $(1.44) in the prior year, reflecting improvements in operating and net losses despite continued investments in commercial and clinical initiatives for its Zephyr Valve therapy. These results highlight growing adoption of their therapy both domestically and internationally, supported by ongoing R&D and clinical trials.
LUNG Technical Analysis & ETF Price Forecast
This article provides a technical analysis and price forecast for Pulmonx Corp (LUNG) ETF. It indicates a "Neutral" overall consensus based on technical sentiment, with specific moving average indicators suggesting a "Buy" signal for LUNG, despite the stock trading below its 60-day and 200-day moving averages. The analysis includes momentum indicators like RSI and MACD, support and resistance levels, and various other technical indicators.
Pulmonx (NASDAQ: LUNG) expands emphysema device business but remains unprofitable
Pulmonx Corporation (NASDAQ: LUNG), a medical technology company specializing in minimally invasive devices for severe emphysema, reported increased revenue of $90.5 million in 2025, up from $83.8 million in 2024, yet sustained a net loss of $54.0 million. The company continues to expand its Zephyr Valve sales, primarily through a direct sales force in the U.S., Europe, and Asia Pacific, while also developing the AeriSeal System to broaden its treatable patient population. Despite revenue growth and advanced product development, Pulmonx faces ongoing challenges including significant net losses, competition, regulatory hurdles, and reimbursement complexities, highlighting its need for additional capital to fund operations and achieve profitability.
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33)
Pulmonx reported 2025 revenue of $90.5 million, an 8.0% increase year-over-year, driven by higher procedure volumes. The company's loss per share improved to $(1.33) from $(1.44) as it continued to narrow operating and net losses while investing in commercial and clinical initiatives for its Zephyr Valve therapy. These results highlight increasing adoption among physicians and hospitals, along with ongoing R&D efforts.
Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens
Pulmonx Corporation (LUNG) reported a decrease in revenue and a widening diluted loss per share for Q4 2025, with revenue down 4.9% year over year to $22.6 million and diluted loss per share at -$0.25. Insider trading activity showed significant sales, and institutional investors displayed mixed sentiment with both substantial additions and removals of shares. Analysts have issued "Buy" ratings and mixed price targets, with a median target of $5.0.
Soleus group holds 2.67M Pulmonx shares (LUNG) — 6.5% stake disclosed
Soleus Capital Master Fund, L.P. and affiliated entities have reported a 6.5% beneficial ownership stake in Pulmonx Corporation (LUNG), totaling 2,665,100 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, calculated based on Pulmonx's outstanding shares as of October 31, 2025. The filing clarifies that while the shares are held directly by the Master Fund, other entities and Guy Levy disclaim beneficial ownership except for Section 13(d) obligations.
Pulmonx (NASDAQ: LUNG) adds $60M loan with Perceptive and issues warrants
Pulmonx Corporation has secured a new senior secured term loan facility of up to $60.0 million from Perceptive Credit Holdings V, LP, drawing an initial $40.0 million. The facility includes two additional $10.0 million tranches contingent on specific revenue targets being met by late 2027. In connection with this financing, Pulmonx issued warrants to Perceptive to purchase 1,000,000 common shares and fully repaid and terminated its previous credit facility with Canadian Imperial Bank of Commerce.
Earnings Preview For Pulmonx
Pulmonx (NASDAQ: LUNG) is set to announce its quarterly earnings on Wednesday, March 4, 2026, with analysts estimating an EPS of $-0.39. Despite beating EPS estimates last quarter, the stock price dropped, and over the past 52 weeks, shares are down 81.32%. The article also highlights Pulmonx's strong financial metrics, including a positive revenue growth trend, impressive net margin, and high returns on equity and assets, despite its stock performance.
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript
Pulmonx Corporation reported its Q4 and full-year 2025 earnings, with Q4 revenue at $22.6 million, a 5% decrease year-over-year, and full-year revenue up 8% to $90.5 million. CEO Glen French outlined a strategy to reaccelerate U.S. sales growth, advance clinical initiatives like the AeriSeal CONVERT II trial, and align spending towards profitability, addressing past operational and executional challenges. The company expects full-year 2026 revenue between $90 million and $92 million, anticipating a return to year-over-year growth in the U.S. and international markets by the second half of the year, alongside a significant reduction in cash burn.
Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn
Pulmonx (LUNG) has secured a new senior secured term loan facility of up to $60 million with Perceptive Credit Holdings V, drawing $40 million initially and with access to two additional $10 million tranches. This new facility, maturing in March 2031, refinances their previous agreement with Canadian Imperial Bank of Commerce, providing expanded liquidity for growth. The company also issued warrants to Perceptive, including a 1,000,000-share warrant.
[Form 4] Pulmonx Corp Insider Trading Activity
Pulmonx Corp's Chief Science & Technology Officer, Radhakrishnan Srikanth, engaged in routine equity transactions. He sold 10,483 shares at $1.43 each to cover tax withholding obligations from vested Restricted Stock Units (RSUs) granted between 2022 and 2025. Concurrently, he received a new grant of 175,000 RSUs, which will vest quarterly over four years, bringing his directly held common stock position to 345,736 shares.
Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M
Pulmonx (Nasdaq: LUNG) reported its Q4 and full-year 2025 financial results, with full-year revenue reaching $90.5 million, an 8% increase year-over-year. The company narrowed its net loss to $54.0 million for 2025 and refinanced its debt, securing a $60 million credit facility. Pulmonx provided guidance for 2026, projecting revenues between $90 million and $92 million, with an approximate 75% gross margin.
Pulmonx Corporation (LUNG) Posts Fourth Quarter Loss, Surpasses Revenue Projections
Pulmonx Corporation (LUNG) reported a narrower-than-expected fourth-quarter loss of $0.25 per share, outperforming the estimated $0.39 loss and marking a 35.9% positive earnings surprise. The company also surpassed revenue projections, generating $22.6 million against an expectation of $22.25 million for the quarter ending December 2025. Despite these positive results, Pulmonx shares have declined about 30.8% year-to-date, and the stock currently holds a Zacks Rank #3 (Hold).
Device for severe emphysema: Pulmonx secures up to $60M credit line
Pulmonx (Nasdaq: LUNG) has secured a five-year credit facility of up to $60 million with Perceptive Advisors, which includes an initial $40 million term loan to refinance existing debt and a potential additional $20 million by late 2027 based on revenue milestones. The agreement extends its debt maturity to 2031 with interest-only payments, aiming to strengthen its capital structure and allow the company to focus on commercial strategy and clinical programs for its minimally invasive treatments for severe emphysema. The market reacted moderately positively, with LUNG shares increasing by 4.86% after the announcement.
Earnings Preview For Pulmonx
Pulmonx (NASDAQ: LUNG) is scheduled to announce its quarterly earnings on March 4, 2026, with analysts expecting an EPS of $-0.39. The company's past performance shows that its stock price dropped after beating EPS estimates, and its shares are down 81.32% over the last 52 weeks. Financially, Pulmonx boasts a strong market capitalization, positive revenue trend with 5.47% growth, impressive net margin of -64.91%, strong ROE of -21.62%, and effective ROA of -9.78%, along with a low debt-to-equity ratio of 0.94.
LUNG Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Pulmonx Corp (LUNG), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Key financial metrics such as gross margin (74.65%), operating margin (-66.94%), net margin (-64.91%), and Return on Equity (-73.73%) are presented. The company's market capitalization stands at $62.90M, and its gross margin is benchmarked against competitors NRXS (83.30%) and OM (42.36%).
Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Esperion (ESPR)
This article highlights bullish sentiments from financial analysts on several healthcare stocks, specifically Pulmonx (LUNG), Esperion (ESPR), and 908 Devices (MASS). Analysts reiterated Buy ratings for all three companies, providing price targets and discussing their individual performance metrics and market consensus. The report underscores the optimistic outlook within the Healthcare sector by these analysts.
LUNG Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Pulmonx Corp (LUNG), including income statements, balance sheets, and cash flow statements from SEC filings. It details key financial metrics, growth rates, and an assessment of financial health across various indicators such as profitability, leverage, liquidity, and cash flow quality. The analysis highlights the company's strong revenue growth and liquidity but points to ongoing unprofitability and low earnings quality.
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Pulmonx Corporation (Nasdaq: LUNG) announced it will release its fourth quarter and full year 2025 financial results on Wednesday, March 4, 2026, after market close. Company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with a webcast available on their "Investors" section. Pulmonx focuses on minimally invasive treatments for COPD, including the FDA-approved Zephyr Endobronchial Valve.
Lung disease treatment firm Pulmonx sets March 4 date for 2025 results
Pulmonx (Nasdaq: LUNG) announced it will report its fourth quarter and full year 2025 financial results on Wednesday, March 4, 2026, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with a webcast available on the company’s investor website. The announcement led to a positive market reaction, with LUNG gaining 5.99% on the day the news was published.
Analyst Jason Kolbert Maintains Buy Rating for Pulmonx (LUNG) at $14 Target | LUNG Stock News
D. Boral Capital analyst Jason Kolbert has reaffirmed a Buy rating for Pulmonx (LUNG) with an unchanged price target of $14.00 USD. This decision reflects continued confidence in the medical technology company, which specializes in minimally invasive treatments for severe emphysema. Other analysts have made varying adjustments to their ratings and price targets over the past few months, with the average target price from six analysts currently at $5.75, suggesting a significant upside from its current price.
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Pulmonx Corporation (Nasdaq: LUNG) announced it would release its financial results for the fourth quarter and full year of 2025 on March 4, 2026, after market close. The company's management will host a conference call to discuss these results, and a webcast will be available on its investor relations website. Pulmonx focuses on minimally invasive treatments for COPD, including its FDA-approved Zephyr Endobronchial Valve.
